Skip to content
Companies

Barreleye US

AI ultrasound analysis for breast and liver diagnosis

Raised to date

$11.3M

of $11.3M offered across 1 Form D filing

Investors
4
Last filed
May 5, 2026

About

Barreleye develops AI-based quantitative ultrasound diagnostic software that analyzes raw radio-frequency (RF) ultrasound signals rather than only B-mode images. Its deep-learning models extract tissue characterization information that previously required MRI, using standard ultrasound hardware. The company sells two product families, the Intelligent series (breast, hepatic, lung) and the Vision series (breast, cardiac, thyroid), and its breast ultrasound software has been designated an innovative medical device and cleared by Korea's MFDS. Founded in 2021 out of KAIST by Professor Hyeonmin Bae, it filed this Form D through its US entity, Barreleye US, Inc., in San Jose, California.

Reads the underlying RF signal from conventional ultrasound probes instead of only the rendered image, which the company says surfaces microscopic tissue changes normally visible only on MRI, so hospitals get MRI-grade tissue information from ultrasound machines they already own.

Funding

  • EquityFiled May 5, 2026Form D
    $11.3M/ $11.3M

Product

Vis-BUS

Medical imaging software

An AI breast ultrasound detection and analysis system that connects to a conventional ultrasound machine over HDMI and gives clinicians real-time or frozen-frame diagnostic feedback on breast lesions.

  • Lesion Detection AI (LD-AI) locates lesions in B-mode images using an EfficientNet backbone with a bi-directional feature network
  • Lesion Analysis AI (LA-AI) scores malignancy likelihood with a fully convolutional network
  • Cancer Probability Score from -100 to 100 with BI-RADS category recommendations

Built for

Hospitals, radiology departments and ultrasound equipment makers

People on file